DESCRIPTION (provided by applicant): Personalized medicine is a new clinical pardigm where a specific cancer therapeutic is prescribed based upon the individual biology of the patient. For example, specific receptor tyrosine kinase (rTK) inhibitors may be chosen based on the proteomic profile of… More

DESCRIPTION (provided by applicant) "Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the individual biology of the patient. A goal of personalized medicine is to select individual therapies based upon the correlation of… More

DESCRIPTION (provided by applicant): Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the individual biology of the patient. A goal of personalized medicine is to select individual therapies based upon the correlation of… More

DESCRIPTION (provided by applicant): Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the correlation of proteomic profiles from diseased tissues with patient's response to drug therapy. Many of these new "smart drug"… More

DESCRIPTION (provided by applicant): The main objective of this project is to develop membranes with surfaces tailored for specific affinity for a particular protein or nucleic acid molecule. These 'smart' membranes will be used in the next generation of high throughput Layered Expression Scanning… More

DESCRIPTION (provided by applicant): Tumor markers, measured in peripheral blood, could assist in diagnosis and management of non-small cell lung cancer (NSCLC) and potentially improve historically dismal outcomes. Circulating antibodies, generated to a wide range of tumor-associated proteins, can… More

DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies,… More

DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or oth er procedures. When used in concert with… More

DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies,… More

DESCRIPTION (provided by applicant): SBIR grant support is being sought by 20/20 GeneSystems, Inc. (20/20), a small biotech company, to help us advance what we believe will become the first blood test to be routinely employed to aid in the early detection of head and neck cancer. Despite recent… More

DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or oth er procedures. When used in concert with… More

This contract was awarded by the National Cancer Institute's Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) Program under the funding opportunity "Contract Topic: 277 Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine… More

DESCRIPTION (provided by applicant): The promise of personalized medicine relies on the development of diagnostic tests to categorize patients within small cohorts who will benefit from specific treatments. 20/20 GeneSystems, Inc. (20/20) is a small business concern focused on the development of… More